Acumen Pharmaceuticals Inc

NASDAQ ABOS

Data sourced from iex and EODHD
Download Data

Acumen Pharmaceuticals Inc Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2024

Acumen Pharmaceuticals Inc Interest Expense To Sales is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability.
  • Acumen Pharmaceuticals Inc Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00%.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email